Joseph Sullivan, MD

Mary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.

Kelly Knupp, MD; Mary Anne Meskis; and Tracy Dixon-Salazar, PhD, share education around patient advocacy and support groups as well as other resources for patients with Dravet syndrome or LGS.

Tracy Dixon-Salazar, PhD, leads a discussion on challenges of treating LGS and real-world implications from clinical trial data on newer medications.

Kelly Knupp, MD, provides insight on optimizing treatment for patients with Lennox-Gastaut Syndrome.

Dr Kelly Knupp examines data on fenfluramine and cannabidiol for the management of Lennox-Gastaut Syndrome.

Joseph E. Sullivan, MD, leads a discussion on treatment options for the management of patients with LGS and considers the impact of treatment on quality of life.

Kelly Knupp, MD, shares her perspective of a provider journey of a new patient with LGS and goal setting to manage the disease.

Tracy Dixon-Salazar, PhD, reflects on her daughter’s journey to diagnosis of Lennox-Gastaut Syndrome and the impact of the disease on caregivers.

Tracy Dixon-Salazar, PhD, and Kelly Knupp, MD, emphasize key identifiers for the diagnosis of Lennox-Gastaut Syndrome and challenges in managing seizures in these patients.

Kelly Knupp, MD, provides an overview of Lennox-Gastaut Syndrome (LGS).

Joseph E. Sullivan, MD, and Kelly Knupp, MD, share strategies for managing patients who have suboptimal seizure control with medications.

Joseph E. Sullivan, MD, and Kelly Knupp, MD, evaluate the use of stiripentol in clinical practice for the management of Dravet syndrome and Mary Anne Meskis discusses the honeymoon effect of drugs.

Expert pediatric neurologists assess the use of fenfluramine and comment on its impact on seizure freedom for patients with Dravet syndrome.

Kelly Knupp, MD, reviews available treatment options indicated for Dravet syndrome and shares her thoughts on the use of cannabidiol for patients.

Kelly Knupp, MD, leads a discussion on goals of treatment for patients who are earlier in their treatment journey.

Progress in therapeutics and diagnosis over the past decade has dramatically shifted the treatment landscape for this genetic epilepsy and rapidly advanced patient care.

Dr Kelly Knupp, Dr Joseph E. Sullivan, and Mary Anne Meskis comment on the impact of Dravet syndrome on a patient and their caregiver’s quality of life and address education around SUDEP.

Kelly Knupp, MD, reviews the patient presentation of Dravet syndrome and the recognition of common signs and symptoms in patients.

Kelly Knupp, MD; Joseph E. Sullivan, MD; and Mary Anne Meskis review diagnosis of Dravet syndrome and the role of genetic testing.

Kelly Knupp, MD, provides an overview of Dravet syndrome and shares insight on discerning the diagnosis of disease from febrile seizures.

Joseph Sullivan, MD, and Elaine C. Wirrell, discuss the transition of care into adulthood of patients with Dravet syndrome.

Key opinion leaders discuss managing patient expectations regarding clinical trials for Dravet syndrome treatment.

A discussion of new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.

The impact of new drug approvals on the consensus guidelines for the treatment of Dravet syndrome.

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

The panel discusses future gene therapies in development for Dravet syndrome.

Joseph Sullivan, MD, provides an overview of the recent approval of fenfluramine oral solution for the treatment of Dravet syndrome.

Elaine C. Wirrell, MD, provides an overview of cannabidiol oral solution for treatment of seizures associated with Dravet syndrome.

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the management of seizures for Dravet syndrome with different approved therapies.

Experts discuss the goals of treatment of patients with Dravet syndrome regarding seizure freedom and seizure burden.